Author + information
- Received August 19, 2019
- Revision received November 6, 2019
- Accepted November 17, 2019
- Published online February 3, 2020.
- Jeffrey I. Mechanick, MDa,∗ (, )@drmikefarkouh,
- Michael E. Farkouh, MD, MScb,
- Jonathan D. Newman, MD, MPHc and
- W. Timothy Garvey, MDd,e
- aZena and Michael A. Wiener Cardiovascular Institute/Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, New York
- bPeter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre, University of Toronto, Toronto, Ontario, Canada
- cDivision of Cardiology and Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University Medical Center, New York, New York
- dDepartment of Nutrition Sciences and Diabetes Research Center, University of Alabama at Birmingham, Birmingham, Alabama
- eGeriatric Research Education and Clinical Center, Birmingham VA Medical Center, Birmingham, Alabama
- ↵∗Address for correspondence:
Dr. Jeffrey I. Mechanick, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1030, New York, New York 10029.
• The CMBCD prevention care plan is designed to implement early, sustainable, and multimodality protocols for all patients with CVD.
• Behavior, adiposity, insulin resistance, dysglycemia, and other MetS traits are the principal targets of the CMBCD preventive care plan for CHD, HF, and AF.
• Structured lifestyle change involving healthy eating patterns and physical activity, judicious use of cardioprotective pharmacotherapy based on cardiovascular outcome trial data, and bariatric procedures are emphasized.
In the second part of this JACC State-of-the-Art Review, an early and sustainable preventive care plan is described for cardiometabolic-based chronic disease. This plan can improve cardiometabolic health by targeting early mechanistic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation). Included are various prevention modalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/metabolic procedures. A tactical approach of implementing published clinical practice guidelines/algorithms for early behavioral, adiposity, and dysglycemia targeting is emphasized, as well as relevant educational and research implications.
- atrial fibrillation
- chronic disease
- type 2 diabetes
Dr. Mechanick has received honoraria from Abbott Nutrition International. Dr. Farkouh has received research grants from Amgen, Novartis, and Novo Nordisk. Dr. Newman has received research grants from the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (K23HL125991); and has received honoraria from Creative Educational Concepts. Dr. Garvey has served on ad hoc advisory boards for Sanofi, Novo Nordisk, Boehringer Ingelheim, Gilead, Amgen, BOYDSense, and the American Medical Group Association; and has conducted research sponsored by the University of Alabama at Birmingham funded by Sanofi, Merck/Pfizer, Novo Nordisk, AstraZeneca, and Lexicon.
- Received August 19, 2019.
- Revision received November 6, 2019.
- Accepted November 17, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.